

Special Issue

Recent Advances in Pharmacology of Pulmonary Hypertension

Message from the Guest Editor

Pulmonary hypertension (PH) is a life-threatening disease caused by the narrowing or blockage of pulmonary vessels. High blood pressure in the pulmonary circulation strains the right side of the heart, leading to right heart failure—a major cause of death for patients with PH. With the development of new drugs, the prognosis of PH has been improving. However, it is still poor and survival is too short; more than 30% of patients die within 5 years of diagnosis. Therefore, advancements in the treatment of PH are needed to improve patient prognosis. This Special Issue has the aim to deepen and broaden our understanding of the pharmacological sciences in the field of PH to develop better therapeutic strategies. Submissions regarding new drug targets, molecular mechanisms of drug action, and novel approaches to therapeutics, including original papers and reviews, are of particular interest.

Guest Editor

Dr. Masashi Tawa

Faculty of Pharmacy, Osaka Medical and Pharmaceutical University,
Takatsuki, Japan

Deadline for manuscript submissions

closed (31 December 2022)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/116908

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)